Market revenue in 2020 | USD 314.6 million |
Market revenue in 2027 | USD 1,268.3 million |
Growth rate | 22% (CAGR from 2020 to 2027) |
Largest segment | Recombinant non-glycosylated proteins |
Fastest growing segment | Recombinant Glycosylated Proteins |
Historical data | 2016 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2027 |
Quantitative units | Revenue in USD million |
Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 54.61% in 2020. Horizon Databook has segmented the Japan biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan biosimilars market , including forecasts for subscribers. This country databook contains high-level insights into Japan biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account